natgillin/translations-raw huggingface dataset:
The method according to claim 1, wherein reagent (M-reag) is selected from the group consisting of p-toluenesulfonylmethyl isocyanide, benzenesulfonyimethyl isocyanide and mixtures thereof. 
Postupak prema jednom ili više zahtjeva 1 do 3, naznačen time da reagens (M-reag.) bude odabran iz skupine koja se sastoji iz p-toluolsulfonilmethilizocijanida, benzolsulfonilmethilizocijanida i njihovih mješavina.
from 20% to 38% by weight of a solvent selected from a ketone, ester, alcohol or mixture thereof based on the weight of the nail coating composition; 
do 0,4% trimetilolpropan trimetakrilata; od 20% do 38% otapala izabranog iz grupe koju čine keton, ester, alkohol ili njihove smjese;
Compounds of the formula I as claimed in claims 1 to 12 in which 
Spojevi formule I u skladu s patentnim zahtjevima 1 do 12, gdje U jeN,
This hydrochloride salt was recrystallized from a mixture of methanol and ether to give 380 mg. of the title compound (cis-racemate, 11% yield, m.p. 
Ova klorhidratna sol se rekristalizira iz smjese metanola i etera tako da se dobiva 380 mg. naslovnog spoja (cis-recemat.
Also disclosed is an isolated polynucleotide comprising a nucleic acid encoding an isolated mutant staphylococcal leukocidin subunit polypeptide comprising, consisting of, or consisting essentially of a wild-type staphylococcal leukocidin subunit except for 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, or more amino acid substitutions at conserved residues, which reduce toxicity of the mutant leukocidin subunit relative to the corresponding wild-type leukocidin subunit; where the wild-type leukocidin subunit comprises, consists of, or consists essentially of the amino acid consensus sequence presented here as SEQ ID NO: 4. 
Izolirani mutant polipeptida divljeg tipa stafilokokne podjedinice leukocidina koji sadrži SEQ ID NO: 5, 6 ili 15, naznačen time što mutant polipeptida stafilokokne podjedinice leukocidina sadrži aminokiselinsku supstituciju na položaju koji odgovara K97 u SEQ ID NO: 6 što smanjuje toksičnost mutanta podjedinice leukocidina u odnosu na odgovarajuću podjedinicu divljeg tipa leukocidina; ili izolirani mutant polipeptida divljeg tipa stafilokokne podjedinice leukocidina koji sadrži SEQ ID NO: 16, 17,21, 22,23, 24, 25 ili 26, pri čemu mutant stafilokokne podjedinice leukocidina sadrži aminokiselinsku supstituciju na položaju koji odgovara K102 u SEQ ID NO: 17, što smanjuje toksičnost mutanta podjedinice leukocidina u odnosu na odgovarajuću podjedinicu divljeg tipa leukocidina.
The cup-shaped part 40 is preferably arranged inside collar 23 as in the above described embodiments. 
Dio 40 u obliku čašice nalazi se ponajprije unutar prstena 23, kao što je opisano u gornjim izvedbama.
wherein (i) the regulatory RNA is selected from the group consisting of antisense ssRNA, ribozyme and decoy RNA, (ii) there is an absence from the minicells of a construct for in situ expression of the regulatory RNA, and (iii) the plurality comprises a therapeutically effective amount of the regulatory RNA. 
Postupak oblikovanja mini-stanica pripravka prema zahtjevu 1, obuhvaća u puferu zajedničku inkubaciju (A) mnoštva intaktnih, bakterijski dobivenih mini-stanica s (B) regulatornom RNA bez plazmida, pri čemu se dobiju mini-stanice koje sadrže tu regulatornu RNA, gdje se ta regulatorna RNA izabire iz grupe koja obuhvaća siRNA, MIRNA i shRNA.
the prevention of reactivation of tuberculosis; or 
(d) sprječavanju reaktiviranja tuberkuloze; ili
The 3,11b- cis -dihydrotetrabenazine used in the invention may be in substantially pure form, for example at an isomeric purity of greater than 90%, typically greater than 95% and more preferably greater than 98%. 
Cis-dihidrotetrabenazin Izomer A koji se koristio u izumu može biti u gotovo čistom obliku, na primjer u izomernoj čistoći većoj od 90%, obično većoj od 95% te je posebno povoljno kada je čistoća veća od 98%.
A computer program product stored on a computer readable storage medium, which when run controls a base station apparatus which transmits, to a mobile station apparatus, a physical downlink control channel, PDCCH, in a search space, to perform the following steps, comprising: transmitting to the mobile station apparatus, in the search space, the PDCCH including a first mobile station identity or a second mobile station identity, wherein the search space is defined based on the first mobile station identity, in a case that the mobile station apparatus has the first mobile station identity and the second mobile station identity; the PDCCH is used for dynamic scheduling when the PDCCH includes the first mobile station identity; and the PDCCH is used for activating persistent scheduling when the PDCCH includes the second mobile station identity. 
Uređaj bazne stanice koji je prilagođen za odašiljanje, na uređaj mobilne stanice, kontrolnog kanala fizičke silazno veze, PDCCH, u prostoru pretraživanja, naznačen time da uređaj bazne stanice sadrži: sredstva podešena za odašiljanje na uređaj mobilne stanice, u prostoru pretraživanja, te PDCCH sadrži identitet prve mobilne stanice ili identitet druge mobilne stanice, pri čemu je prostor pretraživanja određen na temelju identiteta prve mobilne stanice, u slučaju da uređaj mobilne stanice ima identitet prve mobilne stanice i identitet druge mobilne stanice; PDCCH se koristi za dinamično raspoređivanje kada PDCCH sadrži identitet prve mobilne stanice; a PDCCH se koristi za aktiviranje trajnog raspoređivanja kada PDCCH sadrži identitet druge mobilne stanice.
Medium comprising (6-hydroxy-2,5,7,8-tetramethylchroman-2-yl)(4-(2-hydroxyethyl)piperazin-1-yl)methanone in its racemic or enantiomeric form and cells. 
Sredstvo, naznačeno time, da sadrži (6-hidroksi-2,5,7,8-tetrametilkroman-2-11)(4-(2-hidroksietil)piperazin-1-il) metanon u svojem racemičnom ili enantiomernom obliku i stanice.
A pharmaceutical composition comprising a therapeutically effective amount of a salt according to any one of claims 1 to 6 and optionally at least one pharmaceutically acceptable carrier, diluent, vehicle or excipient, preferably wherein the composition is in a form selected from the group consisting of tablets, pills, capsules, pellets, granules, powders, lozenges, sachets, cachets, patches, elixirs, suspensions, dispersions, emulsions, solutions, syrups, aerosols, ointments, soft and hard gelatin capsules, suppositories, sterile injectable solutions, and sterile packaged powders, 
Farmaceutski pripravak, naznačen timešto sadrži terapeutski učinkovitu količinu soli prema bilo kojem od zahtjeva 1 do 611 izborno najmanje jedan farmaceutski prihvatljiv nosač, razrjeđivač, vehikulum ili ekscipijent, poželjno gdje je sastav u obliku odabranom iz grupe koja se sastoji od tableta, pilula, kapsula, peleta, granula, prašaka, pastila, vrećica, paketića, flastera, eliksira, suspenzija, disperzija, emulzija, otopina, sirupa, aerosola, masti, mekih 1 tvrdih želatinskih kapsula, supozitorija, sterilnih imjekcijskih otopina, 1 sterilnih zapakiranih prašaka, poželjnije gdje je pripravak pogodan za primjenu oralnim, transdermalnim ili topikalnim putem.
The method according to claim 1, wherein the monitoring equipment includes a plurality of mats, each of the plurality of mats comprising a detector which includes an antenna configured to detect electromagnetically passage of a participant in the race separately from other participants in the race. 
Sustav u skladu s patentnim zahtjevom 5 ili 6, naznačen time što najmanje dva segmenta trkačke staze sadrže strunjače, gdje svaka od strunjača sadrži detektor za detektiranje prolaska sudionika.
is a group according to general formula (6) wherein n=1, 2, 3 or 4 
je skupina u skladu s općom formulom (6) pri čemu n = 1, 2, 3 ili 4
Compound of Formula I Content (%) 
Kristalni polimorf koji sadrži spoj Formule I:
The support structure of claim 1, wherein the pad layer is attached to the second side of the base via adhesive, thermal bonding, welding, mechanical attachment, or a combination thereof. 
Podni sklop u skladu s patentnim zahtjevom 7, naznačen time što je navedeni pokrovni sloj (11) pričvršćen na navedeni osnovni materijal (6) najmanje jednim od ljepila, toplinskog vezanja, zavarivanja, te mehaničkog pričvršćivanja.
According to a further feature of this aspect of the invention there is provided a method for producing an anti-proliferative effect in a warm-blooded animal, such as man, in need of such treatment which comprises administering to said animal an effective amount of a quinazoline derivative of the Formula I, or a pharmaceutically acceptable salt thereof, as hereinbefore defined. 
Prema dodatnom aspektu ovog izuma, objavljen je postupak za postizanje antiproliferativnog učinka u toplokrvnoj životinji, poput čovjeka, kojoj je takvo liječenje potrebno, a koji se sastoji od davanja spomenutoj životinji efektivne doze derivata kinazolina prikazanog Formulom I, ili njegove farmaceutski prihvatljive soli, u skladu sa definicijom u gornjem tekstu.
converting a compound of formula (Ia-5) into a compound of formula (Ia-6), by reaction with in the presence of a suitable catalyst, a suitable solvent, and a suitable base, wherein R2 to R7, p, q and X are defined as in claim 1; 
ba pri čemu W, predstavlja pogodnu odlaznu skupinu i pri čemu su RU, R* do R', p, q i X kako je definirano u patentnom zahtjevu 1; f) pretvorbu spoja formule (1a-5) u Spoj formule (1a-6), reakcijom sa u prisutnosti pogodnog katalizatora, pogodnog otapala i pogodne baze, ha
The method of claim 9, wherein the GPR119 agonist has an EC50 of less than 10 uM. 
Uporaba u skladu sa zahtjevom 37, naznačena time, da GPR119 agonist ima EC50 manji od 10 uM.
C3-6 cycloalkyl optionally substituted with one or two groups selected from C1-6 alkyl, -CN, and halo; or 5-memberedheterocyclyl; 
C3-6 cikloalkil opcionalno supstituiran s jednom ili dvije skupine odabrane od sljedećih: -6 alkil, –CN i halo; ili 5-članiheterociklil;
A process for extracting a roll-holder cartridge (3) from a working position, inside a rolling mill stand according to claim 6, to a side position (3') outside said stand (13) for changing the working rolls (2), the process comprising the following steps: 
Postupak vađenja držača valjaka (3) iz radnog položaja, unutar valjačkog stana prema zahtjevu 6, u bočni položaj (3’) izvan stana (13) radi zamjene radnih valjaka (2), postupak obuhvaća sljedeće korake:
The composition of any one of claims 1 to 4, wherein the method of treating multiple sclerosis is increasing walking speed in a patient with multiple sclerosis. 
Sastav prema bilo kojem od zahtjeva 1 do 4, naznačen time da je postupak tretiranja multiple skleroze povećanje brzine hoda kod pacijenta s multiplom sklerozom.
The anti-CGRP receptor antibody or antigen-binding fragment thereof for use according to claim 11 wherein the other migraine headache prophylactic therapy is an antiepileptic, a tricyclic antidepressant, or a beta-blocker. 
Protutijelo anti-CGRP receptora ili njegov ulomak koji veže antigen za uporabu prema patentnom zahtjevu 11 naznačeno time što druga profilaktička terapija migrenske glavobolje je antiepileptik, triciklički antidepresiv ili beta blokator.
A compound according to claim 1 which is 2-fluoro-4-(1-(S-3-methoxypropan-2-yl)-6-methanesulfonylamino-1H-indol-3-yl)-benzonitrile, or a pharmaceutically acceptable salt thereof. 
Spoj u skladu s patentnim zahtjevom 1, naznačen time što je 2-fluor-4-(1-(S-3-metoksipropan-2-il)-6-metansulfonilamino-1H-indol-3-il)benzonitril, ili njegova farmaceutski prihvatljiva sol.
An isolated humanized antibody or antibody fragment thereof that specifically binds to IL-13, wherein the antibody or antibody fragment thereof comprises a variable light chain comprising the amino acid sequence of SEQ ID NO: 1 and comprises a variable heavy chain comprising the amino acid sequence of SEQ ID NO: 2. 
Izolirano protutijelo ili njegov fragment protutijela koji se specifično veže na IL-4, naznačeno time da protutijelo ili njegov fragment protutijela je humaniziran, te pri čemu protutijelo ili njegov fragment protutijela sadrži varijabilni lagani lanac koji sadrži sekvencu aminokiseline iz SEQ ID NO: 3 i sadrži varijabilni teški lanac koji sadrži sekvencu aminokiseline iz SEQ ID NO: 4.
The compound according to claim 1 which is (S)—N-(4-Fluorophenyl)-4-(4-(4-fluorophenyl)phthalazin-1-yl)-2-methylpiperazine-1-carboxamide, or a pharmaceutically acceptable salt thereof. 
Spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 9, naznačen time što je (S)-N-(4-fluorfenil)-4-(4-(4- fluorfenil)ftalazin-1-11)-2-metilpiperazin-1-karboksamid, ili njegova farmaceutski prihvatljiva sol.
converting Compound 26 to Compound 27: 
prevođenju Spoja 26 u Spoj 27:
sodium butyrate is added 24 hours post-transfection without changing the medium of the culture; and 
- < natrijev butirat se dodaje 24 sata nakon transficiranja bez izmjene uzgojnog medija; i
The method according to claim 6, wherein the L1 signaling information further has PLP PAYLOAD TYPE information which indicates a type of payload data carried by an associated PLP. 
Metoda u skladu s patentnim zahtjevom 6, pri čemu informacija signaliziranja L1 nadalje ima informaciju vrste podataka PLP polja koja ukazuje vrstu podataka polja koje prenosi pridruženi PLP.
A combination according to claim 8 wherein the active compound (c) is selected from the group consisting of (a) B2-agonists and (b) cortiocosteroids. 
Kombinacija u skladu s patentnim zahtjevom 8, naznačena time, da je djelatna tvar (c) odabrana iz skupine koja se sastoji od (a) inhibitora PDE IV 1 (b) f2 agonista.
and wherein aryl or heterocyclyl substituents of (C6-C10)aryl and (C5-C10)heterocyclyl groups may not be further substituted by an aryl or heterocyclyl containing group; 
te gdje arilni ili heterociklilni supstituenti (C6-C10)arilnih i (C5-C10)heterociklilnih skupina ne mogu biti daljnje supstituirani sa skupinom koja sadrži aril ili heterociklil;
A combination according to claim 9, wherein the active compound (c) is selected from the group consisting of (i) PDE IV inhibitors and (b) cortiocosteroids. 
Kombinacija sukladno patentnom zahtjevu 9, naznačena time, da je djelatni spoj (c) odabran iz skupine koja se sastoji od (a) inhibitora PDE IV i (b) kortikosteroida.
moving apart the mould portions (310, 320) to release the container (100) from there-between. 
HR P20161168 T1 razdvaja dijelove kalupa (310, 320) radi otpuštanja posude (100) iz tog međuprostora.
FIG. 5 depicts the in vitro immunosuppressive activity of rapamycin, 42-O-(D-fructosylcarbonyl)rapamycin and a carbamate-linked analog of 42-O-(D-fructosylcarbonyl)rapamycin. 
Slika 5 - prikazuje imunosupresivnu aktivnost rapamicina, 42-O-(D-fruktozilkarboniljrapamicina i analoga 42-0-(D- fruktozilkarboniljrapamicina vezanog na karbamat in vitro.
The receiving method according to claim 8, wherein the portion of the bits necessary to indicate the allocated plurality of clusters are LSBs, Least Significant Bits of the resource allocation information, and/or wherein the remaining bits(s) are MSBs, Most Significant Bits, of the resource allocation information, and the defined value is zero. 
Postupak prijenosa prema zahtjevu 9, naznačen time da su dio bitova potrebnih za označavanje dodijeljenog pluraliteta klastera LSB-ovi, Najmanje Bitni Bitovi, podatka o dodjeli resursa.
A developer supply container according to claim 1, wherein said drive converting portion (2d, 3b) converts the rotational force received by said gear portion (2a) to the force for operating said pump portion (2b) to reciprocate said pump portion (2b). 
Spremnik za nadopunjavanje razvijača u skladu s patentnim zahtjevom 14, naznačen time što navedeni dio za pretvorbu pogona (2d, 3b) pretvara silu vrtnje na takav način da kada je navedena pregrada (17) u zatvorenom položaju, gdje navedeni crpni dio (2b) vrši usis kroz navedeni otvor za ispuštanje (3).
When the non-digestible oligosaccharide A and/or B is a mixture, the averages of the respective parameters are used for defining the present invention. 
Hrana u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačena time što je ne-fermentirana hrana za dojenčad i/ili dijete.
production of an oily paste by means of crushing of olives; 
proizvodnje uljne paste drobljenjem maslina;
providing a microwave-transparent container holding the organic material to be dehydrated; 
(a) osiguravanja mikrovalno-transparentne posude (38) koja sadrži organski materijal (40) koji treba da se dehidrira;
The Rapamycin Carbohydrate Derivatives 
Ugljikohidratni derivati rapamicina
• cutting of said solid batch in the length direction of the first and the second timber boards. 
rezanje navedenog krutog stoga u smjeru duljine prve i druge drvene ploče.
This complex is further taste masked by coating. 
Ovom kompleksu se nadalje maskira okus oblaganjem.
The device according to claim 1 or 2, wherein the RBG size is greater than one. 
Integrirani krug sukladno zahtjevu 1 ili 2, naznačen time da je u drugoj dodjeli, dodijeljen jedan ili više RBG-a uređaju mobilnoj stanici.
The antisense oligonucleotide according to claim 6, wherein the modified backbone is selected from the group consisting of a morpholino backbone, a carbamate backbone, a siloxane backbone, a sulfide backbone, a sulfoxide backbone, a sulfone backbone, a formacetyl backbone, a thioformacetyl backbone, a methyleneformacetyl backbone, a riboacetyl backbone, an alkene containing backbone, a sulfamate backbone, a sulfonate backbone, a sulfonamide backbone, a methyleneimino backbone, a methylenehydrazino backbone and an amide backbone. 
Oligonukleotid u skladu s patentnim zahtjevom 5, naznačen time što je nukleotidni analog LNA (blokirana nukleinska kiselina). Oligonukleotid u skladu s patentnim zahtjevom 4, naznačen time što se modificiranu okosnicu bira iz skupine koju čine morfolino okosnica, karbamatna okosnica, siloksanska okosnica, sulfidna okosnica, sulfoksidna okosnica, sulfonska okosnica, formacetilna okosnica, tioformacetilna okosnica, metilenformacetilna okosnica, riboacetilna okosnica, okosnica koja sadrži alken, sulfamatna okosnica, sulfonatna okosnica, sulfonamidna okosnica, metilenimino okosnica, metilenhidrazino okosnica i amidna okosnica.
The drug-delivery device of claim 1, wherein the ophthalmic drug is a prostaglandin, triamcinolone, icomucret, or rimexolone. 
Naprava za unos lijeka u skladu s patentnim zahtjevom 1, naznačena time što je oftalmički lijek prostaglandin, triamcinolon, ikomukret ili rimeksolon.
Item 14b. A process for producing a freeze-dried aripiprazole formulation comprising the steps of (d') reducing the mean particle size of aripiprazole in a primary suspension formed by mixing aripiprazole, a vehicle for the aripiprazole, and water to the range of about 1 to about 10 microns to form a final suspension; 
Postupak za proizvodnju zamrzavanjem osušene formulacije aripiprazola prema zahtjevu 14, naznačen time da sadrži korake (d") smanjivanje srednje veličine čestica aripiprazola u primarnoj suspenziji nastaloj miješanjem aripiprazola, nosača za aripiprazol, te vode u raspon od oko 1 do oko 10 mikrona da se dobije konačna suspenzija;
<Explanation of main parts of the drawings> 
Datum podnošenja europske prijave patenta:
The composition according to claim 18, wherein the beta2-adrenoceptor agonist is selected from enantiomerically pure or enantiomerically enriched R-enantiomer of Amiterol, Bamethan, Bitolterol, Butaxamine, Carbuterol, Cimaterol, Colterol, Clenbuterol, Clorprenaline, Colterol, Deterenol, Dioxethedrin, Etafedrine, Ethylnorepinephrine, Fenoterol, Indacaterol, Isoproterenol, Mabuterol, Meluadrine, Nardeterol, Norbudrine, Norepinephrine, Orciprenaline, Picumeterol, Pirbuterol, Quinprenaline, Reproterol, Salbutamol, Salmeterol, Soterenol, Sulfonterol, Terbutaline, Tulobuterol, Zinterol, and a pharmaceutically acceptable salt thereof. 
Pripravak prema zahtjevu 18, naznačen time da je agonist beta2-adrenoceptora odabran od enantiomerno čistog ili enantiomerno obogaćenog R-enantiomera od Amiterola, Bametana, Bitolterola, Butaksamina, Karbuterola, Cimaterola, Kolterola, -Klenbuterola, Klorprenalina, Kolterola, Deterenola, Dioksetedrina, Etafedrina, Ftilnorepinefrina, Fenoterola, Indakaterola, Izoproterenola, Mabuterola, Meluadrina, Nardeterola, Norbudrina, Norepinefrina, Orciprenalina, Pikumeterola, Pirbuterola, Kvinprenalina, Reproterola, Salbutamola, Salmeterola, Soterenola, Sulfonterola, Terbutalinea, Tulobuterola, Zinterola, i njegova farmaceutski prihvatljiva sol. .
A pharmaceutical composition for treating Alzheimer's disease, cerebrovascular dementia, Parkinson's disease, ischemic apoplexy, pain, intractable depression, attention deficit hyperactivity disorder, migraines, schizophrenia, generalized anxiety disorder, obsessive-compulsive disorder, autism, bulimia, or drug addiction, which comprises the compound or a pharmaceutically acceptable salt thereof of (1), or 4a-phenyl-2,3,4,4a,5,9b-hexahydro-1H-indeno[1,2-b]pyridine or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient. 
Farmaceutski sastav, naznačen time, da je za liječenje Alzheimer-ove bolesti, cerebrovaskularne demencije, Parkinson-ove bolesti, ishemijske apopleksije, bolova, neukrotive depresije, poremećaja hiperaktivnosti s nedostatkom pažnje, migrena, shizofrenije, poremećaja opće anksioznosti, opsesivno-kompulzivnog poremećaja, autizma, bulimije ili ovisnosti o drogama, te da obuhvaća spoj ili njegovu farmaceutski prihvatljivu sol prema zahtjevu 1, ili 4a-fenil-2,3,4,4a,5,9b-heksahidro-1H-indeno[1,2-b]piridin ili njegovu farmaceutski prihvatljivu sol kao i farmaceutski prihvatljivo pomoćno sredstvo.
sealing together said joined edges (23) of the part-formed bag (22) around a portion of the bag periphery, leaving said opening (24) in one side; 
(c) hermetički spajanje navedenih spojenih rubova (23) djelomično oblikovane vrećice (22) oko dijela perifernog područja navedene vrećice, pri čemu se na jednoj strani ostavlja navedeni otvor (24);
The construct for the use of claim 12, wherein a CD19xCD3 bispecific single chain antibody construct induces a graft-versus-leukemia (GvL) effect. 
Konstrukt namijenjen upotrebi u skladu s patentnim zahtjevom 12, naznačen time što CD19xCD3 bispecifično jednolančano protutijelo kao konstrukt potiče učinak presatka prema leukemiji (GvL).
The composition of claim 14, which consists of a) about 10% by weight terbinafine HCl, b) about 0.3% by weight hydroxypropyl chitosan, c) about 19.7% by weight purified water and d) about 70% by weight ethanol. 
Pripravak prema patentnom zahtjevu 14, koji se sastoji od a) oko 10 % masenog udjela terbinafin HC1-a, b) oko 0,3 % masenog udjela hidroksipropil hitozana, c) oko 19,7 % masenog udjela pročišćene vode i d) oko 70 % masenog udjela etanola.
The pharmaceutical preparation according to claim 3 which is used as a vasodilator, hypotensive drug, aquaretic agent, or platelet aggregation inhibitor. 
Farmaceutski pripravak prema zahtjevu 3, naznačen time, da se upotrebljava kao vazodilatorsko sredstvo, lijek za snižavanje krvnog tlaka, akvaretičko sredstvo, 1li kao inhibitor agregacije pločastih stanica.
wherein the inner skirt (16) is secured to the inside of the frame (12), the inner skirt (16) comprising a weave of a first set of strands with a second set of strands, both the first and second sets of strands being non-parallel with the axial direction of the prosthetic aortic valve (10); 
Sklop prema patentnom zahtjevu 11 ili 12, naznačen time da nadalje obuhvaća unutrašnju suknju (16), pri čemu vanjska suknja (18) ima u osnovi ravnu donju ivicu (160), pričvršćenu donjom ivicom unutrašnje suknje (16) na dovodnom kraju zaliska.
The receiver can be turned on by a separate switch which is preferably installed near the control station of the yacht. 
Prijemnik se može uključiti pomoću zasebne sklopke koja je po mogućnosti postavljena u blizini kontrolne stanice na jahti.
The method according to claim 20, wherein said treatment comprises the degradation and/or modification of cellulose and/or hemicellulose and/or a pectic substance. 
Postupak prema zahtjevu 11 i/ili zahtjevu 12, naznačen time da obrada obuhvaća degradaciju i/ili modifikaciju celuloze i/ili hemiceluloze i/ili pektinske tvari.